HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Junghans, U. Articles by Siebler, M. Search for Related Content PubMed PubMed Citation Articles by Junghans, U. Articles by Siebler, M. Related Collections MRI All Cerebrovascular disease/Stroke Clinical trials Observational study (Cohort, Case control) Infarction

Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban

From the Department of Neurology (Drs. Junghans, Seitz, Ritzl, Fink, Freund, and Siebler) and Institute of Diagnostic Radiology (Dr. Wittsack), University Hospital Düsseldorf, Germany.

Address correspondence and reprint requests to Prof. Dr. M. Siebler, Department of Neurology, University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany; e-mail: siebler{at}uni-duesseldorf.de

In an open pilot study, the authors tested whether the nonpeptide glycoprotein (GP) IIb/IIIa antagonist tirofiban, a highly effective and selective blocker of platelet aggregation, prevents the transition of ischemic brain tissue into the infarct proper as defined by MRI (perfusion-weighted/T2-weighted) in patients with acute ischemic stroke. The infarct volume (T2 lesion after 1 week) was smaller in treated patients (n = 10) compared with matched control subjects (n = 10; p = 0.029) with similar initial perfusion deficit (TTP-maps). The authors conclude that GP IIb/IIIa antagonists have therapeutic potential in acute stroke therapy.

This article has been cited by other articles:

				C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF]

				C. A. Molina and J. L. Saver Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies Stroke, October 1, 2005; 36(10): 2311 - 2320. [Abstract] [Full Text] [PDF]

				S. Straub, U. Junghans, V. Jovanovic, H. J. Wittsack, R. J. Seitz, and M. Siebler Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion Stroke, March 1, 2004; 35(3): 705 - 709. [Abstract] [Full Text] [PDF]

				R. J. Seitz, M. Hamzavi, U. Junghans, P. A. Ringleb, C. Schranz, and M. Siebler Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations Stroke, August 1, 2003; 34(8): 1932 - 1935. [Abstract] [Full Text] [PDF]

				S. Hahnel, P. D. Schellinger, A. Gutschalk, K. Geletneky, M. Hartmann, M. Knauth, and K. Sartor Local Intra-arterial Fibrinolysis of Thromboemboli Occurring During Neuroendovascular Procedures With Recombinant Tissue Plasminogen Activator Stroke, July 1, 2003; 34(7): 1723 - 1728. [Abstract] [Full Text] [PDF]

				U. Junghans and M. Siebler Cerebral Microembolism Is Blocked by Tirofiban, a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Receptor Antagonist Circulation, June 3, 2003; 107(21): 2717 - 2721. [Abstract] [Full Text] [PDF]

				Can GP IIb/IIIa Inhibitors Help in Ischemic Stroke? Journal Watch Emergency Medicine, April 17, 2002; 2002(417): 7 - 7. [Full Text]